<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809211</url>
  </required_header>
  <id_info>
    <org_study_id>ICORG 08-02</org_study_id>
    <secondary_id>ICORG 08-02</secondary_id>
    <secondary_id>EUDRACT-2008-004551-30</secondary_id>
    <secondary_id>EU-20899</secondary_id>
    <nct_id>NCT00809211</nct_id>
  </id_info>
  <brief_title>Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase II Multi-center, Open-label, Study of Nilotinib at a Dose of 300mg Twice Daily in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Trials Ireland</source>
  <brief_summary>
    <textblock>
      RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well nilotinib works in treating patients with&#xD;
      newly diagnosed chronic phase chronic myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish the complete cytogenetic response rate at 6 months in patients with newly&#xD;
           diagnosed Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia&#xD;
           treated with nilotinib.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To establish the complete cytogenetic response rate at 3, 9, 12, 18, and 24 months in&#xD;
           these patients.&#xD;
&#xD;
        -  To establish the molecular response rate at 3, 6, 9, 12, 18, and 24 months in these&#xD;
           patients.&#xD;
&#xD;
        -  To establish the safety of this drug in these patients.&#xD;
&#xD;
        -  To correlate pharmacokinetic data with response rate and toxicity.&#xD;
&#xD;
        -  To correlate Bcr-Abl results using GeneXpert with Bcr-Abl results using international&#xD;
           standardized quantitative PCR.&#xD;
&#xD;
        -  To estimate the prevalence of Bcr-Abl mutations prior to and during treatment.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral nilotinib twice daily on days 1-28. Treatment repeats every 28 days for&#xD;
      up to 24 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Peripheral blood and bone marrow samples are collected periodically for mutation analysis,&#xD;
      Bcr-Abl analysis by quantitative PCR, metaphase cytogenetics, and pharmacokinetic analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete cytogenetic response rate at 6 months as assessed by metaphase analysis</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular response rate at 3, 6, 9, 12, 18, and 24 months as assessed by quantitative PCR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of event-free survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of pharmacokinetic data with response rate and toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Bcr-Abl results using GeneXpert with Bcr-Abl results using international standardized quantitative PCR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Bcr-Abl mutations prior to and during treatment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Cytogenetically confirmed chronic myelogenous leukemia (CML) by standard conventional&#xD;
             cytogenetic analysis of bone marrow*&#xD;
&#xD;
               -  Newly diagnosed disease (within the past 6 months) NOTE: *FISH cannot be used&#xD;
&#xD;
          -  In chronic phase, as defined by the following:&#xD;
&#xD;
               -  Less than 15% blasts in peripheral blood and bone marrow&#xD;
&#xD;
               -  Less than 30% blasts plus promyelocytes in peripheral blood and bone marrow&#xD;
&#xD;
               -  Less than 20% basophils in peripheral blood&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
               -  No evidence of extramedullary leukemic involvement, except for hepatosplenomegaly&#xD;
&#xD;
          -  Philadelphia chromosome-positive disease as demonstrated by (9;22) translocation&#xD;
             (presence of Bcr-Abl)&#xD;
&#xD;
               -  A review of ≥ 20 metaphases is required&#xD;
&#xD;
          -  No previously documented T315I mutations&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Estimated glomerular filtration rate ≥ 30 mL/min&#xD;
&#xD;
          -  Serum amylase and lipase ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (unless related to CML)&#xD;
&#xD;
          -  Potassium ≥ lower limit of normal (LLN)&#xD;
&#xD;
          -  Magnesium ≥ LLN&#xD;
&#xD;
          -  Phosphorous ≥ LLN&#xD;
&#xD;
          -  Total calcium ≥ LLN (corrected for serum albumin)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No impaired cardiac function including, but not limited to, any of the following:&#xD;
&#xD;
               -  LVEF &lt; 45% or &lt; LLN by ECHO&#xD;
&#xD;
               -  Inability to determine the QT interval on ECG&#xD;
&#xD;
               -  Complete left bundle branch block&#xD;
&#xD;
               -  Congenital long QT syndrome or a known family history of long QT syndrome&#xD;
&#xD;
               -  History of or presence of clinically significant ventricular or atrial&#xD;
                  tachyarrhythmias&#xD;
&#xD;
               -  Clinically significant resting bradycardia (&lt; 50 beats/min)&#xD;
&#xD;
               -  QTc &gt; 450 msec on an average of 3 serial baseline ECGs (using the QTcF formula)&#xD;
&#xD;
               -  Clinically documented myocardial infraction within the past 12 months&#xD;
&#xD;
               -  Unstable angina within the past 12 months&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., congestive heart failure or&#xD;
                  uncontrolled hypertension)&#xD;
&#xD;
          -  No severe or uncontrolled medical condition (e.g., uncontrolled diabetes or active or&#xD;
             uncontrolled infection)&#xD;
&#xD;
          -  No history of significant congenital or acquired bleeding disorder unrelated to CML&#xD;
&#xD;
          -  No history of non-compliance to medical regimens&#xD;
&#xD;
          -  No other primary malignancy unless it is neither currently clinically significant nor&#xD;
             requiring active intervention&#xD;
&#xD;
          -  No impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of the study drug (e.g., ulcerative disease, uncontrolled nausea,&#xD;
             vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass&#xD;
             surgery)&#xD;
&#xD;
          -  No acute pancreatitis within the past year&#xD;
&#xD;
          -  No history of chronic pancreatitis&#xD;
&#xD;
          -  No acute or chronic liver, pancreatic, or severe renal disease considered unrelated to&#xD;
             CML&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior therapy for CML other than hydroxyurea and/or anagrelide&#xD;
&#xD;
          -  Prior imatinib mesylate allowed provided it was administered for ≤ 14 days&#xD;
&#xD;
          -  More than 30 days since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy and biologic agents&#xD;
&#xD;
          -  No concurrent strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole,&#xD;
             itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil)&#xD;
&#xD;
          -  No concurrent strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine,&#xD;
             rifampin, rifabutin, rifapentin, phenobarbital, St. John's wort)&#xD;
&#xD;
          -  No concurrent medications that have the potential to prolong QT interval&#xD;
&#xD;
          -  No concurrent grapefruit, star fruit, Seville oranges, or their derivatives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike O'Dwyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Centre</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 24, 2019</submitted>
    <returned>February 15, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

